drugset / Trial / NCT05470855

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

NCT05470855

Phase 4 Unknown 45400 enrolled Sinovac (Dalian) Vaccine Technology Co., Ltd.
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the protective effect of varicella vaccine in children aged 1-12 years and the correlation between varicella antibody and protective effect,to evaluate the immunogenicity and safety of varicella vaccine in children aged 1-12 years.

Timeline

Start
2022-07-06
Primary completion
2022-11-30
Completion
2023-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Live Attenuated Varicella Vaccine Vaccine 0.5 ml Intramuscular

Indications